GNI Group Ltd. (TYO:2160)
2,192.00
-100.00 (-4.36%)
Nov 18, 2026, 10:40 AM JST
GNI Group Revenue
GNI Group had revenue of 17.79B JPY in the quarter ending September 30, 2026, with 150.45% growth. This brings the company's total for the last twelve months to 37.21B, up 44.37% year-over-year. In the year 2025, GNI Group had annual revenue of 26.84B with 13.68% growth. That makes GNI Group the 16,399th largest company in the world by revenue and 1,776th in Japan.
Revenue (ttm)
37.21B
Revenue Growth
+44.37%
P/S Ratio
4.05
Revenue / Employee
37.59M
Employees
990
Market Cap
144.32B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full GNI Group breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.84B | 3.23B | 13.68% |
| Dec 31, 2024 | 23.61B | -2.40B | -9.22% |
| Dec 31, 2023 | 26.01B | 8.59B | 49.33% |
| Dec 31, 2022 | 17.42B | 4.73B | 37.26% |
| Dec 31, 2021 | 12.69B | 2.92B | 29.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nxera Pharma | 35.51B |
| PeptiDream | 20.48B |
| 3-D Matrix | 11.92B |
| RaQualia Pharma | 4.02B |
| Heartseed | 3.03B |
| Japan Tissue Engineering | 2.68B |
| Cuorips | 72.00M |
| Healios K.K. | 47.00M |
GNI Group News
- 5 months ago - GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company - GlobeNewsWire